Re trial. My memory was the anticipated path would be:
- likely recruit 2x patients per month
- aiming for 10 patients
- split 7 internal Lymphoma, 3 skin lymphoma
Length of time trial to run for was not, as far as I could remember, explicitly stated. What was stated was that average length of response to "current standard of care treatment" was 4 months. some respond for longer, some shorter.
And a follow up comment was made that, due to average length of response to current treatment being 4 months, that (to paraphrase), it would not take a lengthy trial to determine whether the drug was working
Implies, to me:
- if all goes to plan there will be 10 patients recruited from Oct, 2021. Through to Feb 2022.
- If last patients recruited Feb 2022. Six months after Feb 2022 is August 2022. Add on time to analyse data.
It will take a while before there is meaningful data that could be shared. At most out-rageously optimistic - End Q1 2022. Slighlty more realistic but still extremely optimistic - end Q2 2022. Starting to feel like it is realistic optimism - end Q3 2022.
- Forums
- ASX - By Stock
- PTX
- ptx-100 presentation
ptx-100 presentation, page-4
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PTX (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.0¢ |
Change
0.001(2.56%) |
Mkt cap ! $32.21M |
Open | High | Low | Value | Volume |
4.0¢ | 4.0¢ | 4.0¢ | $8.763K | 219.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 58342 | 3.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
4.1¢ | 168410 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 58342 | 0.039 |
6 | 551544 | 0.038 |
8 | 387500 | 0.037 |
5 | 708916 | 0.036 |
4 | 303590 | 0.035 |
Price($) | Vol. | No. |
---|---|---|
0.041 | 168410 | 3 |
0.042 | 337500 | 2 |
0.043 | 504602 | 3 |
0.045 | 222151 | 4 |
0.047 | 13339 | 1 |
Last trade - 15.13pm 02/10/2024 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |